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Chemical biology is an interdisciplinary field of study that is often defined as “chemistry-
initiated biology.” As biological processes all stem from chemical events, it should be possible 
to understand or manipulate biological events by using chemistry. Our laboratory has been 
discovering or designing unique organic molecules that modulate fundamental processes in 
human cells. Such synthetic organic molecules often serve as tools for basic cell biology. 
Discovery or design of small molecules with unique biological activity permits small- 
molecule initiated exploration of complex cellular events. Our mission is to create a new 
world of bioactive synthetic molecules: their new way to use, their new shapes, and their new 
sizes. We hope to open new avenues for small-molecule applications in a range of fields, in-
cluding future concepts in drug discovery and use of small molecules for cell therapy.
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A Small Molecule That Promotes Cardiac 
Differentiation of Human Pluripotent Stem 
Cells under Defined Cytokine- and Xeno-free 
Conditions
Human pluripotent stem cells (hPSCs), including 
 embryonic stem cells and induced pluripotent stem cells, 
are potentially useful in regenerative therapies for heart 
disease. For medical applications, clinical-grade cardiac 
cells must be produced from hPSCs in a defined, cost- 
effective manner. Cell-based screening led to the discovery 
of KY02111, a small molecule that promotes differentia-
tion of hPSCs to cardiomyocytes. Although the direct 
 target of KY02111 remains unknown, results of the present 
study suggest that KY02111 promotes differentiation by 
inhibiting WNT signaling in hPSCs but in a manner that is 
distinct from that of previously studied WNT inhibitors. 
Combined use of KY02111 and WNT signaling modula-
tors produced robust cardiac differentiation of hPSCs in a 
xeno-free, defined medium, devoid of serum and any kind 
of recombinant cytokines and hormones, such as BMP4, 
Activin A, or insulin. The methodology has potential as a 
means for the practical production of human cardiomyo-
cytes for regeneration therapies.
Mis-localization and Inhibition of ACC1 by a 
Synthetic Small Molecule
Chromeceptin is a synthetic small molecule that inhibits 
insulin-induced adipogenesis of 3T3-L1 cells and impairs 
the function of insulin-like growth factor 2 (IGF2). The 
molecular target of this benzochromene derivative is 
 multifunctional protein 2 (MFP-2). The interaction between 
chromeceptin and MFP-2 activates the signal transducer 
and activator of transcription 6 (STAT6), which subse-
quently induces IGF inhibitory genes. It was not previously 
known how the binding of chromeceptin with MFP-2 
blocks adipogenesis and activates STAT6. Results of the 
present study showed that the chromeceptin/MFP-2 
 complex binds to and inhibits acetyl-CoA carboxylase 1 
(ACC1), an enzyme important for the de novo synthesis 
of malonyl-CoA and fatty acids. The formation of this 
 ternary complex removes ACC1 from the cytosol and 
 sequesters it in peroxisomes through guidance of Pex5p. 
As a result, chromeceptin impairs fatty acid synthesis 
from acetate where ACC1 is a rate limiting enzyme. Over-
expression of malonyl-CoA decarboxylase or siRNA 
knockdown of ACC1 resulted in STAT6 activation, sug-
gesting a role of malonyl-CoA in STAT6 signaling. The 
molecular mechanism of chromeceptin may provide a new 
pharmacological approach to selective inhibition of ACC1 
for biological studies and pharmaceutical development.
